Kairos Pharma, Ltd. (KAPA)

NYSEAMERICAN: KAPA · Real-Time Price · USD

0.5980

-0.0410 (-6.42%)

At close: May 28, 2025, 4:00 PM

0.5821

-0.0159 (-2.66%)

After-hours: May 28, 2025, 5:55 PM EDT

Kairos Pharma Employees

As of December 31, 2024, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees.

Employees

4

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$885,500

Market Cap

9.94M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	4	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000
AbbVie	55,000

Employee Rankings

KAPA News

22 days ago - Kairos Pharma, Ltd. Announces Participation in the D. - Newsfile Corp
4 weeks ago - Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire
4 weeks ago - Kairos Pharma Ltd. Provides Letter to Stockholders - Business Wire
5 weeks ago - Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer - Business Wire
2 months ago - Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer - Business Wire
2 months ago - Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events - Business Wire
2 months ago - Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer - Business Wire
3 months ago - Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma - Business Wire